Literature DB >> 15907670

A prospective study of adverse reactions to the weaning of opioids and benzodiazepines among critically ill children.

Céline Ducharme1, Franco A Carnevale, Marie-Sol Clermont, Sarah Shea.   

Abstract

The aim of this study was to identify the optimal rates at which opioids and benzodiazepines should be weaned in order to prevent withdrawal reactions in the pediatric intensive care unit (PICU). This study follows an earlier investigation that developed a graphical analysis method for examining behavioral signs of withdrawal in relation to changes in opioid and benzodiazepine administration. This method was utilized in this present study for a prospective sample of all patients admitted to a tertiary/quaternary level PICU within a 4-week interval (n=27). The findings of this study indicate that the required rate of weaning (in order to prevent withdrawal reactions) is related to the number of days the child has been on a continuous infusion of opioids and/or benzodiazepines. Adverse withdrawal reactions were prevented when the daily rate of weaning did not exceed: 20% for children receiving continuous infusions for 1-3 days; 13-20% for 4-7 days; 8-13% for 8-14 days; 8% for 15-21 days; and 2-4% for more than 21 days of infusions. The authors recommend that the rate of weaning of opioids and benzodiazepines in critically ill children be tailored to the length of time the child received continuous infusions of these agents.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15907670     DOI: 10.1016/j.iccn.2004.09.003

Source DB:  PubMed          Journal:  Intensive Crit Care Nurs        ISSN: 0964-3397            Impact factor:   3.072


  11 in total

Review 1.  Optimising drug dosing in patients receiving extracorporeal membrane oxygenation.

Authors:  Vesa Cheng; Mohd-Hafiz Abdul-Aziz; Jason A Roberts; Kiran Shekar
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

2.  Sedation and analgesia in the PICU: many questions remain.

Authors:  Sandra Prins; Monique van Dijk; Dick Tibboel
Journal:  Intensive Care Med       Date:  2006-05-13       Impact factor: 17.440

Review 3.  Risk factors associated with iatrogenic opioid and benzodiazepine withdrawal in critically ill pediatric patients: a systematic review and conceptual model.

Authors:  Kaitlin M Best; Joseph I Boullata; Martha A Q Curley
Journal:  Pediatr Crit Care Med       Date:  2015-02       Impact factor: 3.624

4.  Use of methadone for prevention of opioid withdrawal in critically ill children.

Authors:  Sonia A Jeffries; Rumi McGloin; Alexander F Pitfield; Roxane R Carr
Journal:  Can J Hosp Pharm       Date:  2012-01

5.  The Impact of a Clonidine Transition Protocol on Dexmedetomidine Withdrawal in Critically Ill Pediatric Patients.

Authors:  JiTong Liu; Jessica Miller; Michael Ferguson; Sandra Bagwell; Jonathan Bourque
Journal:  J Pediatr Pharmacol Ther       Date:  2020

6.  Impact of a Standardized Treatment Guideline for Pediatric Iatrogenic Opioid Dependence: A Quality Improvement Initiative.

Authors:  Rima Abdouni; Teri Reyburn-Orne; Tarek H Youssef; Imad Y Haddad; Richard D Gerkin
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Jan-Feb

Review 7.  Withdrawal symptoms in children after long-term administration of sedatives and/or analgesics: a literature review. "Assessment remains troublesome".

Authors:  Erwin Ista; Monique van Dijk; Claudia Gamel; Dick Tibboel; Matthijs de Hoog
Journal:  Intensive Care Med       Date:  2007-06-01       Impact factor: 17.440

8.  Practice guidelines for sedation and analgesia management of critically ill children: a pilot study evaluating guideline impact and feasibility in the PICU.

Authors:  Samantha J Keogh; Debbie A Long; Desley V Horn
Journal:  BMJ Open       Date:  2015-03-30       Impact factor: 2.692

9.  Iatrogenic Opioid Withdrawal Syndrome in Critically Ill Patients: a Retrospective Cohort Study.

Authors:  Dong Gon Hyun; Jin Won Huh; Sang Bum Hong; Younsuck Koh; Chae Man Lim
Journal:  J Korean Med Sci       Date:  2020-04-20       Impact factor: 2.153

Review 10.  The role of systematic reviews in pharmacovigilance planning and Clinical Trials Authorisation application: example from the SLEEPS trial.

Authors:  Carrol Gamble; Andrew Wolf; Ian Sinha; Catherine Spowart; Paula Williamson
Journal:  PLoS One       Date:  2013-03-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.